- Trials with a EudraCT protocol (78)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
78 result(s) found for: mpn.
Displaying page 1 of 4.
EudraCT Number: 2022-001076-34 | Sponsor Protocol Number: ABNL-MARRO-001 | Start Date*: 2023-06-12 | ||||||||||||||||
Sponsor Name:Theradex (Europe) Ltd. | ||||||||||||||||||
Full Title: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes | ||||||||||||||||||
Medical condition: Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003009-31 | Sponsor Protocol Number: HH007 | Start Date*: 2022-12-23 | |||||||||||
Sponsor Name:Zealand University Hospital, dept. of Haematology | |||||||||||||
Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis | |||||||||||||
Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001406-42 | Sponsor Protocol Number: 30032016 | Start Date*: 2016-12-20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001203-36 | Sponsor Protocol Number: BHT-II-002 | Start Date*: 2019-01-09 | ||||||||||||||||
Sponsor Name:4D Pharma Plc | ||||||||||||||||||
Full Title: A Phase 2 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix™ in Adult Subjects with Irritable Bow... | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome (IBS), subtypes IBS-C and IBS-D | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Completed) GB (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002132-25 | Sponsor Protocol Number: 12-181 | Start Date*: 2015-06-29 |
Sponsor Name:University Hospital Aachen AöR, represented by the executive board, represented by the Dean of the Medical Faculty | ||
Full Title: RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial | ||
Medical condition: Myeloproliferative Neoplasms (MPN): high-risk Polycythemia Vera (PV) and high-risk Essential Thrombocythemia (ET) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000607-36 | Sponsor Protocol Number: ACE-536-MF-002 | Start Date*: 2021-06-01 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOM... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) IE (Trial now transitioned) GR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004874-41 | Sponsor Protocol Number: NMDSG14A | Start Date*: 2016-07-25 |
Sponsor Name:Nordic MDS study group | ||
Full Title: Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML) | ||
Medical condition: Chronic myelomonocytic leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002281-23 | Sponsor Protocol Number: Spon1345-14 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML) | |||||||||||||
Medical condition: Chronic myelomonocytic leukaemia (CMML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002431-29 | Sponsor Protocol Number: POMINC(MPNSG02-12) | Start Date*: 2013-07-23 |
Sponsor Name:University Hospital of Ulm | ||
Full Title: A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis | ||
Medical condition: Patients with Primary and Secondary Myelofibrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002007-35 | Sponsor Protocol Number: AVENHIR | Start Date*: 2023-03-02 | |||||||||||
Sponsor Name:Groupe Francophone des Myélodysplasies (GFM) | |||||||||||||
Full Title: Phase II study with safety run-in of Azacitidine (AZA) combined with Venetoclax (VEN) in patients with higher-risk Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
Medical condition: Newly diagnosed, HMA-naïve, higher-risk (HR, defined as CPSS risk intermediate-2 or high) CMML patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001201-24 | Sponsor Protocol Number: KRT-232-104 | Start Date*: 2019-12-02 | |||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML). | |||||||||||||
Medical condition: Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) BE (Prematurely Ended) HU (Completed) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002318-37 | Sponsor Protocol Number: INCB18424-357 | Start Date*: 2012-11-06 |
Sponsor Name:Incyte Corporation | ||
Full Title: Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes | ||
Medical condition: Polycythemia Vera | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) IT (Completed) ES (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000322-35 | Sponsor Protocol Number: ACE-536-MF-001 | Start Date*: 2017-08-22 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and With... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004239-21 | Sponsor Protocol Number: PAC325 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:CTI BioPharma Corp. | |||||||||||||
Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemi... | |||||||||||||
Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001048-40 | Sponsor Protocol Number: B1371013 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 | |||||||||||||
Full Title: A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib. | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005497-38 | Sponsor Protocol Number: RG_15-234 | Start Date*: 2016-05-25 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms | |||||||||||||
Medical condition: Myeloproliferative Neoplasms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004370-10 | Sponsor Protocol Number: RUXO_LMMC-PRO_1401 | Start Date*: 2014-03-21 | |||||||||||
Sponsor Name:Grupo Español de Sindromes Mielodisplásicos (GESMD) | |||||||||||||
Full Title: A phase II study of ruxolitinib (INCB018424) to evaluate efficacy and safety in Patients with Proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
Medical condition: Proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002452-37 | Sponsor Protocol Number: IMG-7289-CTP-202 | Start Date*: 2022-01-27 | |||||||||||
Sponsor Name:Imago BioSciences Inc. | |||||||||||||
Full Title: A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat ... | |||||||||||||
Medical condition: Patients with Myeloproliferative Neoplasms (MPNs) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010738-23 | Sponsor Protocol Number: MPN-SG01-09 | Start Date*: 2009-11-12 |
Sponsor Name:Universitätsklinikum Ulm | ||
Full Title: Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage | ||
Medical condition: This is a phase II, multi-center study of pomalidomide in adult patients with Primary myelofibrosis, Secondary myelofibrosis, and unclassifiable Myeloproliferative Neoplasms showing at least grade ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001847-58 | Sponsor Protocol Number: ARD12042 | Start Date*: 2011-10-12 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or in... | |||||||||||||
Medical condition: polycythemia vera, or essential thrombocythemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
